Key result
Cardiovascular polypill therapy shows early safety and efficacy for reducing CVD risk.
Answers are grounded in this paper and cite their sources.
Cardiovascular diseases (CVD) account for one-third of annual global mortality. The aggregated benefits of concurrently controlling common CVD risk factors, such as dyslipidemia and hypertension, in people at overall risk for CVD is postulated to be more efficient than treating each individual risk factor to target. Administration of a polypill consisting of cholesterol-lowering (statins), antihypertensive, and antiplatelet agents together would simultaneously lower multiple risk factors, and applying such a population risk-reduction strategy would drastically reduce CVD incidence. This idea has generated much controversy and debate over the past decade. A few studies have emerged providing early evidence about the safety and efficacy of such a pill, and the results of ongoing and planned studies of outcome are eagerly anticipated. In this article, we review and interpret the existing evidence as well as explore the potential of a polypill for primary and secondary prevention of CVD.
No takes yet. Share an insight, caveat, or question.
Dabhadkar et al. (2011) conducted a review in Cardiovascular disease. Cardiovascular polypill (statins, antihypertensives, and antiplatelet agents) vs. Treating individual risk factors to target was evaluated on Cardiovascular disease incidence. Cardiovascular polypill therapy combining statins, antihypertensives, and antiplatelets shows early evidence of safety and efficacy for reducing CVD risk, though outcome studies are still ongoing.
Synapse has enriched 10 related papers. Consider them for comparative context: